Oppenheimer Maintains a 'Perform' on Teva Pharma (TEVA); Wait for Clarity on Pipeline
Tweet Send to a FriendGet Alerts TEVA Hot Sheet
Price: $40.23 +0.68%
Rating Summary:
7 Buy, 16 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
7 Buy, 16 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade TEVA Now!
Oppenheimer maintains a 'Perform' on Teva Pharma (NASDAQ: TEVA).
Analyst, Christopher Holterhoff, said, "TEVA reported 2Q12 adj. EPS of $1.28, slightly above our $1.27 est., on rev. of $~5B, vs. our est. of ~$5.1B. We note that TEVA launched 12 products during the quarter, representing $17B in brand value. TEVA purchased ~3.5M shares ($35M aggregate spend) during 2Q12 ($667M aggregate spend on $3B repurchase program in 1H12). We highlight that TEVA also paid down ~$500M in debt and refinanced $3.4B of short-term debt which improved debt-to-EBITDA ratio to 2.2x from 2.6x. We adjust our estimates and look for insight from management into long-term strategic initiatives, pipeline developments, and BD commentary at the 12/11 Analyst Day."
FY12 EPS Estimate raised from $5.38 to $5.40 and FY13 from $5.91 to $6.01.
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $38.10 yesterday, with a 52 week range of $35.00-$46.65.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Christopher Holterhoff, said, "TEVA reported 2Q12 adj. EPS of $1.28, slightly above our $1.27 est., on rev. of $~5B, vs. our est. of ~$5.1B. We note that TEVA launched 12 products during the quarter, representing $17B in brand value. TEVA purchased ~3.5M shares ($35M aggregate spend) during 2Q12 ($667M aggregate spend on $3B repurchase program in 1H12). We highlight that TEVA also paid down ~$500M in debt and refinanced $3.4B of short-term debt which improved debt-to-EBITDA ratio to 2.2x from 2.6x. We adjust our estimates and look for insight from management into long-term strategic initiatives, pipeline developments, and BD commentary at the 12/11 Analyst Day."
FY12 EPS Estimate raised from $5.38 to $5.40 and FY13 from $5.91 to $6.01.
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $38.10 yesterday, with a 52 week range of $35.00-$46.65.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Compass Point Boosts Numbers on RLJ Lodging Trust (RLJ)
- Needham & Company Downgrades Aruba Networks (ARUN) to Hold
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
